STOCK TITAN

Bicara Therapeutics (BCAX) awards 38,950 stock options to board director

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Bicara Therapeutics Inc. director Christy J. Oliger received a grant of stock options for 38,950 shares of common stock on July 28, 2026. The options have an exercise price of $26.88 per share, expire on July 28, 2036, and vest one-third on July 28, 2027, with the remaining two-thirds vesting in 24 equal monthly installments, subject to her continued service.

Positive

  • None.

Negative

  • None.
Insider Oliger Christy J.
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) F1 38,950 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 38,950 shares (Direct)
Footnotes (1)
  1. F1. One-third of the shares underlying this option shall vest and become exercisable on July 28, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Options Granted 38,950 shares Stock Option (Right to Buy) grant to director on July 28, 2026
Exercise Price $26.88 per share Exercise price of the granted stock options
Expiration Date July 28, 2036 Expiration of the stock options granted to the director
Post-Grant Holdings 38,950 options Total stock options held directly after the reported grant
Initial Vesting One-third on July 28, 2027 First vesting tranche of the option award
Remaining Vesting Schedule 24 monthly installments Remainder of options vesting after initial one-third, subject to service
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 26.8800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares underlying this option shall vest and become exercisable"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-07-28"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
derivative security financial
"transaction_type: derivative"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Bicara Therapeutics (BCAX) disclose in this Form 4?

Bicara Therapeutics reported that director Christy J. Oliger received a grant of stock options for 38,950 shares of common stock. These are derivative awards, not an open-market purchase or sale, and reflect equity-based compensation rather than cash investment or divestment.

What are the key terms of Christy J. Oliger’s stock options at BCAX?

The options cover 38,950 shares of common stock with an exercise price of $26.88 per share and an expiration date of July 28, 2036. They were granted at no cost as compensation and are exercisable only after vesting conditions are met.

How do the Bicara Therapeutics (BCAX) options granted to Christy J. Oliger vest?

One-third of the underlying 38,950 shares vest on July 28, 2027. The remaining two-thirds vest in 24 equal monthly installments after that date, conditioned on Christy J. Oliger’s continued service with Bicara Therapeutics on each vesting date.

Did this BCAX Form 4 involve any open-market buying or selling of shares?

No. The Form 4 reports a grant of stock options, coded as an acquisition (A), not an open-market purchase (P) or sale (S). The transaction reflects equity compensation and does not show cash proceeds or expenditures from trading common stock.

What is Christy J. Oliger’s option position in BCAX after this grant?

Following the transaction, Christy J. Oliger holds 38,950 stock options directly, according to the filing. These options are tied to an equal number of common shares and become exercisable over time as the specified vesting schedule is satisfied.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Oliger Christy J.

(Last)(First)(Middle)
BICARA THERAPEUTICS INC.
116 HUNTINGTON AVENUE, SUITE 703

(Street)
BOSTON MASSACHUSETTS 02116

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$26.8807/28/2026A38,950 (1)07/28/2036Common Stock38,950$038,950D
Explanation of Responses:
1. One-third of the shares underlying this option shall vest and become exercisable on July 28, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Remarks:
/s/ Ryan Cohlhepp, Attorney-in-Fact07/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)